Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene Autoleucel Combined With Sintilimab for R/R B-cell Lymphoma
NCT07077512Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel, sintilimab in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), sponsored by Sun Yat-sen University. Started Sep 2025; status: recruiting.
02
Drugs
relmacabtagene autoleucelsintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07077512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077512.